HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Human immunodeficiency virus infection and viral hepatitis].

Abstract
Hepatic complications currently represent one of the leading reasons for medical consultations, hospitalisation, and death in the HIV-infected population. This is due to a large extent to viral hepatitis, given its disproportionate frequency in this population. Chronic hepatitis B affects 5-10% of the HIV-infected population. Vaccination has reduced the incidence of liver disease related to hepatitis-B virus (HBV), and the availability of tenofovir has dramatically improved the prognosis of HIV/HBV carriers. Delta hepatitis affects around 15% of HIV-infected individuals in Europe harbouring positive HBsAg. It has the worst prognosis, given its accelerated course to cirrhosis and the absence of successful therapy. Lastly, chronic hepatitis C is the major cause of liver disease in the HIV population. Although classically linked to persons infected parenterally (i.e., intravenous drug users), outbreaks of acute hepatitis C among homosexual men have been reported over the last decade. Treatment with pegylated interferon plus ribavirin provides a cure in less than 40% of patients. However, the introduction of new direct acting antivirals against hepatitis- C virus (HCV) (telaprevir, boceprevir) has revolutionised the field, as HAART did in 1996 in the HIV field, improving the prognosis of co-infected patients. However, interactions between these drugs and antiretroviral agents and the risk of selective resistance pose huge threats in this population.
AuthorsVicente Soriano, Luz Martin-Carbonero, Eugenia Vispo, Pablo Labarga, Pablo Barreiro
JournalEnfermedades infecciosas y microbiologia clinica (Enferm Infecc Microbiol Clin) Vol. 29 Issue 9 Pg. 691-701 (Nov 2011) ISSN: 1578-1852 [Electronic] Spain
Vernacular TitleInfección por virus de la inmunodeficiencia humana y hepatitis víricas.
PMID21978797 (Publication Type: English Abstract, Journal Article, Review)
CopyrightCopyright © 2011 Elsevier España, S.L. All rights reserved.
Chemical References
  • Anti-HIV Agents
  • Antiviral Agents
Topics
  • Algorithms
  • Anti-HIV Agents (adverse effects, pharmacology, therapeutic use)
  • Antiviral Agents (adverse effects, pharmacology, therapeutic use)
  • Comorbidity
  • Disease Progression
  • Drug Interactions
  • Drug Monitoring
  • Drug Resistance, Viral
  • Female
  • HIV Infections (complications, drug therapy, epidemiology)
  • Hepatitis B (complications, drug therapy, epidemiology)
  • Hepatitis C (complications, drug therapy, epidemiology)
  • Hepatitis D (complications, drug therapy, epidemiology)
  • Hepatitis, Viral, Human (complications, drug therapy, epidemiology)
  • Humans
  • Male
  • Prognosis
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: